Comparative Pharmacology
Head-to-head clinical analysis: ALOSETRON HYDROCHLORIDE versus ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOSETRON HYDROCHLORIDE versus ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER.
ALOSETRON HYDROCHLORIDE vs ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alosetron is a selective antagonist of the serotonin 5-HT3 receptor. By blocking 5-HT3 receptors in the gastrointestinal tract and central nervous system, it reduces visceral hypersensitivity, colonic motility, and intestinal secretions, thereby alleviating symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D).
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, inhibiting emetic reflex.
1 mg orally twice daily for 4 weeks; if response is inadequate, increase to 1 mg twice daily for an additional 4 weeks.
8 mg IV or 0.15 mg/kg IV every 8 hours for 3 doses or 32 mg IV once over 15 minutes for prevention of chemotherapy-induced nausea, or 4 mg IV once over 2-5 minutes for prevention of postoperative nausea. IV infusion in D5W at concentrations up to 1 mg/mL.
None Documented
None Documented
Terminal half-life is approximately 1.5–2 hours in healthy volunteers; prolonged in hepatic impairment (up to 2.5 hours) but no significant accumulation with repeated dosing.
Terminal elimination half-life is approximately 3-6 hours in adults, but may be prolonged in elderly patients (up to 8 hours) and in patients with severe hepatic impairment (Child-Pugh class C: 15-32 hours).
Renal: ~73% (mostly as metabolites), Fecal: ~24%, Biliary: minor; <1% excreted unchanged in urine.
Approximately 5% of ondansetron is excreted unchanged in urine; the remainder undergoes extensive hepatic metabolism via CYP1A2, CYP2D6, and CYP3A4, with metabolites excreted in urine (about 44-60% of total dose) and feces (about 33-38%).
Category C
Category A/B
5-HT3 Antagonist
5-HT3 Antagonist